李轶男,王萍,陈晖

• 1:首都医科大学附属北京友谊医院心内科

摘要(Abstract)：

<正>冠状动脉微循环障碍是在多种致病因素的作用下,微循环固有的结构和(或)功能异常,损伤心肌灌注,进而引起缺血的临床综合征[1]。既往认为冠状动脉微循环障碍会导致患者出现无症状性心肌缺血,也可表现为心绞痛甚至心肌梗死,会增加不良心血管事件发生的风险,随着研究的深入,冠状动脉微循环障碍可能会造成心肌纤维化,甚至心力衰竭的发生。

关键词(KeyWords)： 冠状动脉微循环障碍;心肌纤维化;心力衰竭

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 李轶男,王萍,陈晖

参考文献(References)：

• [1]Dean J,Cruz SD,Mehta PK,et al.Coronary microvascular dysfunction:sex-specific risk,diagnosis,and therapy.Nat Rev Cardiol,2015,12(7):406-414.
• [2]Rossi MA,Mengel JO.The pathogenesis of chronic Chagas'myocarditis:the role of autoimmune and microvascular factors.Rev Inst Med Trop Sao Paulo,1992,34(6):593-599.
• [3]Moreno-Moral A,Mancini M,D'Amati G,et al.Transcriptional network analysis for the regulation of left ventricular hypertrophy and microvascular remodeling.J Cardiovasc Transl Res,2013,6(6):931-944.
• [4]Mohammed SF,Hussain S,Mirzoyev SA,et al.Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction.Circulation,2015,131(6):550-559.
• [5]闫磊,童嘉毅.冠状动脉微循环障碍概述及研究进展.现代医学,2013,41(8):589-591.
• [6]吴易航,邓翠云.微血管性心绞痛发病机制及治疗研究进展.中外医疗,2017,36(14):196-198.
• [7]Rohr S.Arrhythmogenic implications of fi broblast-myocyte interactions.Circ Arrhythm Electrophysiol,2012,5(2):442-452.
• [8]李永梅,任立群.心肌间质细胞在心肌纤维化中的作用.心血管病学进展,2007,28(4):600-602.
• [9]Chen YF,Wu KJ,Wood WG.Paeonia lactifl ora Extract Attenuating Cerebral Ischemia and Arterial Intimal Hyperplasia Is Mediated by Paeonifl orin via Modulation of VSMC Migration and Ras/MEK/ERK Signaling Pathway.Evid Based Complement Alternat Med,2013,2013:482428.
• [10]Paulus WJ,Tsch?pe C.A novel paradigm for heart failure with preserved ejection fraction:comorbidities drive myocardial dysf unction and remodeling through coronary microvascular endothelial infl ammation.J Am Coll Cardiol,2013,62(4):263-271.
• [11]王禹川,丁燕生,刘梅林.不同因子致心肌纤维化分子学机制.医学综述,2012,18(17):2736-2740.
• [12]Williams SM,Golden-Mason L,Ferguson BS,et al.Class I HDACs regulate angiotensin II-dependent cardiac fi brosis via fi broblasts and circulating fi brocytes.J Mol Cell Cardiol,2014,67:112-125.
• [13]Lindner D,Zietsch C,Tank J,et al.Cardiac fi broblasts support cardiac infl ammation in heart failure.Basic Res Cardiol,2014,109(5):428.
• [14]Creemers EE,Pinto YM.Molecular mechanisms that control interstitial fi brosis in the pressure-overloaded heart.Cardiovasc Res,2011,89(2):265-272.
• [15]Meléndez GC,Mc Larty JL,Levick SP,et al.Interleukin 6mediates myocardial fi brosis,concentric hypertrophy,and diastolic dysfunction in rats.Hypertension,2010,56(2):225-231.
• [16]Kleinbongard P,Schulz R,Heusch G.TNFa in myocardial ischemia/reperfusion,remodeling and heart failure.Heart Fail Rev,2011,16(1):49-69.
• [17]施洋,李澜,邢晓雪,等.心肌纤维化与慢性充血性心力衰竭研究进展.中国临床药理学杂志,2016,32(1):87-90.
• [18]王玉泉,胡厚源.冠状动脉微血管功能障碍在糖尿病性心肌病发病中的作用.重庆医科大学学报,2015,40(11):1383-1386.
• [19]陈章炜,钱菊英,马剑英,等.猪冠状动脉微栓塞模型血清TGF-β_1的表达.中国临床医学,2009,16(2):172-175.
• [20]Hong S,Choo E,Ihm S,et al.Dipeptidyl peptidase 4 inhibitor attenuates obesity-induced myocardial f ibrosis by inhibiting transforming growth factor-βl and Smad2/3 pathways in high-fat dietinduced obesity rat model.Metabolism,2017,76:42-55.
• [21]Pauriah M,Khan F,Lim TK,et al.B-type natriuretic peptide is an independent predictor of endothelial function in man.Clin Sci(Lond),2012,123(5):307-312.
• [22]Hirakawa K,Yamamuro M,Uemura T,et al.Correlation between microvascular dysfunction and B-type natriuretic peptide levels in non-ischemic heart failure patients with cardiac fi brosis.Int J Cardiol,2017,228:881-885.
• [23]刘凯,夏豪,周晓莉,等.心脏X综合征患者血清半乳糖凝集素3的表达和价值研究.临床心血管病杂志,2017,33(4):319-322.
• [24]Meijers WC,van der Velde AR,Pascual-Figal DA,et al.Galectin-3and post-myocardial infarction cardiac remodeling.Eur J Pharmacol,2015,763(Pt A):115-121.
• [25]Mochly-Rosen D,Das K,Grimes KV.Protein kinase C,an elusive therapeutic target?Nat Rev Drug Discov,2012,11(12):937-957.
• [26]苏文,苏兆林,陈晖,等.PKCβ_2途径抑制药物LY333531延缓高糖诱导心肌纤维化的实验研究.医学研究杂志,2015,44(8):14-16.
• [27]Palaniyandi SS,Ferreira JC,Brum PC,et al.PKCβII inhibition attenuates myocardial infarction induced heart failure and is associated with a reduction of fi brosis and pro-infl ammatory responses.J Cell Mol Med,2011,15(8):1769-1777.
• [28]Nako H,Kataoka K,Koibuchi N,et al.Novel mechanism of angiotensin II-induced cardiac injury in hypertensive rats:the critical role of ASK1 and VEGF.Hypertens Res,2012,35(2):194-200.
• [29]Ong P,Athanasiadis A,Sechtem U.Treatment of angina pectoris associated with coronary microvascular dysfunction.Cardiovasc Drugs Ther,2016,30(4):351-356.
• [30]李勇,刘敏.冠状动脉慢血流与冠状动脉微循环障碍的相关性分析.中国实用医药,2018,13(7):34-36.
• [31]Zhang X,Li Q,Zhao J,et al.Effects of combination of statin and calcium channel blocker in patients with cardiac syndrome X.Coron Artery Dis,2014,25(1):40-44.
• [32]Wei LY,Fu XH,Li W,et al.Effect of Intravenous Administration of Liposomal Prostaglandin E1 on Microcirculation in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Intervention.Chin Med J(Engl),2015,128(9):1147-1150.
• [33]贾珠银,瞿小丹,孙家驹,等.替格瑞洛对非ST段抬高急性冠状动脉综合征患者冠状动脉微循环的影响.中国介入心脏病学杂志,2016,24(5):256-260.
• [34]Ong P,Athanasiadis A,Sechtem U.Pharmacotherapy for coronary microvascular dysfunction.Eur Heart J Cardiovasc Pharmacother,2015,1(1):65-71.
• [35]Duvernoy CS.Evolving strategies for the treatment of microvascular angina in women.Expert Rev Cardiovasc Ther,2012,10(11):1413-1419.
• [36]傅向华,肖宇杨,李向明.冠状动脉微循环障碍药物治疗及防治现状.内科理论与实践,2017,12(1):27-32.
• [37]李萌玫,邵一兵,张纯全,等.不同侧支循环患者冠状动脉完全闭塞病变择期经皮冠状动脉介入治疗术后冠状动脉微循环的差异及近期预后的比较.中国介入心脏病学杂志,2016,24(12):672-676.
• [38]李萌玫,邵一兵,张纯全,等.2型糖尿病血糖控制不良合并急性心肌梗死患者择期经皮冠状动脉介入治疗后冠状动脉微循环及近期预后.中国介入心脏病学杂志,2017,25(11):628-633.